Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives ...

During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...

Bristol Myers Squibb Co. raised its revenue outlook for the year after newer medicines outperformed expectations, easing ...

Bristol-Myers Squibb Company BMY reported third-quarter 2025 adjusted earnings per share (EPS) of $1.63, which comfortably ...

Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires ...

MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...

Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and arriving on the scene valued somewhere north of $800 million.

On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...

The U.S. FDA's approval Thursday of Bristol Myers Squibb's (NYSE:BMY) novel antipsychotic Cobenfy (xanomeline and trospium chloride) for schizophrenia could significant influence treatment of the ...

29 August 2024, Bavaria, Munich: The logo of the pharmaceutical company Bristol-Myers Squibb, (BMS) is seen on the facade of the company's Munich headquarters on August 29, 2024 in Munich (Bavaria).

Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive ...

Credit: Bristol Myers Squibb. Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors. Data from the EMERGENT ...